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Abstract
Background: The sexually transmitted disease, gonorrhea, is a serious health problem in developed as well as in
developing countries, for which treatment continues to be a challenge. The recent completion of the genome sequence
of the causative agent, Neisseria gonorrhoeae, opens up an entirely new set of approaches for studying this organism and
the diseases it causes. Here, we describe the initial phases of the construction of an expression-capable clone set
representing the protein-coding ORFs of the gonococcal genome using a recombination-based cloning system.
Results: The clone set thus far includes 1672 of the 2250 predicted ORFs of the N. gonorrhoeae genome, of which 1393
(83%) are sequence-validated. Included in this set are 48 of the 61 ORFs of the gonococcal genetic island of strain MS11,
not present in the sequenced genome of strain FA1090. L-arabinose-inducible glutathione-S-transferase (GST)-fusions
were constructed from random clones and each was shown to express a fusion protein of the predicted size following
induction, demonstrating the use of the recombination cloning system. PCR amplicons of each ORF used in the cloning
reactions were spotted onto glass slides to produce DNA microarrays representing 2035 genes of the gonococcal
genome. Pilot experiments indicate that these arrays are suitable for the analysis of global gene expression in gonococci.
Conclusion: This archived set of Gateway® entry clones will facilitate high-throughput genomic and proteomic studies
of gonococcal genes using a variety of expression and analysis systems. In addition, the DNA arrays produced will allow
us to generate gene expression profiles of gonococci grown in a wide variety of conditions. Together, the resources
produced in this work will facilitate experiments to dissect the molecular mechanisms of gonococcal pathogenesis on a
global scale, and ultimately lead to the determination of the functions of unknown genes in the genome.
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Neisseria gonorrhoeae (gonococcus), a Gram-negative
diplococcus, is one of two pathogenic members of the
Neisseriaceae family of bacteria. N. gonorrhoeae is the caus-
ative agent of the sexually transmitted disease, gonorrhea,
one of the oldest documented infectious diseases. Gonor-
rheal disease has significant morbidity both in the US and
worldwide. According to the Centers for Disease Control
[1], >350,000 cases of gonorrhea were reported in the
United States in 2002. The World Health Organization [2]
estimates that over 19 million cases occur annually in the
African continent alone. Treatment of gonorrhea is
increasingly problematic due to the high frequency of
acquisition of resistance to multiple antibiotics [3,4] and
to the observation that gonococcal infection does not
elicit protective immunity [5]. Gonorrheal infections,
though not usually life-threatening, also enhance the
transmission of HIV [6].
N. gonorrhoeae is strictly a human pathogen, with no
known animal reservoir. The bacterium has no environ-
mental niche, and cannot survive outside the human host.
In adults, N. gonorrhoeae is acquired primarily through
sexual contact. However, the eyes of newborn infants may
be infected by passing through an infected birth canal,
resulting in the condition, ophthalmia neonatorum,
which can lead to blindness. In most cases, gonococcal
infections are limited to the urogenital tract, causing ure-
thritis in men and cervicitis in women. Occasionally,
gonococci cross the epithelial barrier to enter the blood-
stream causing septicemia, and transit to the joints result-
ing in arthritis. In women, ascending infections from the
endocervix can result in pelvic inflammatory disease, salp-
ingitis, tubal blockage and infertility. N. gonorrhoeae can
also establish a carrier state in which apparently healthy
individuals harbor culturable and infectious bacteria [7].
Carriers are thought be important for disease dissemina-
tion. A recent study revealed that the gonococcal carriage
rate in women was 6.7% in a major metropolitan area [8].
Due to the importance of N. gonorrhoeae to human health,
much research effort has focussed on identifying virulence
factors and elucidating the biochemical interactions of
these factors with the host cell [9-11], with the goal of
developing vaccines and alternative treatments. It is clear,
however, that in order to fully understand the capabilities
of this organism to cause disease and elude eradication, it
will be necessary to ultimately determine the functions of
a great deal more of the gene products encoded by the
gonococcal genome. The recent genome sequencing
makes possible a variety of genomic and proteomic stud-
ies of N. gonorrhoeae. To facilitate such studies, we have
cloned into a bacteriophage lambda-based recombination
cloning system (Gateway® [12], Invitrogen, Carlsbad, CA)
1624 of the 2189 predicted ORFs from the genome of N.
gonorrhoeae strain FA1090 [13], and 48 of the 61 ORFs of
the gonococcal genetic island (GGI) of strain MS11
[14,15]. This clone-set allows the generation of transcrip-
tional and translational fusions without the necessity of
additional cloning and sequencing. Coupled to the con-
struction of this clone set, DNA microarrays were gener-
ated by spotting the insert DNA onto glass slides.
Preliminary experiments with the clone set and DNA
arrays indicate that this system is suitable for studies of
expression of genes from N. gonorrhoeae in heterologous
systems as well as for the study of global gene expression
in this organism.
Results
Design of oligonucleotide primers
The goal of this project was to create a plasmid library rep-
resenting the annotated ORFs of N. gonorrhoeae. The Gate-
way® Cloning System from Invitrogen [12] was selected
for several reasons. First, Gateway® uses a recombination-
based cloning method which has the added benefit that
once an archival clone is sequence-validated, subsequent
recombinants (ie. into expression vectors) do not need to
be sequenced. Second, the initial clones lack transcrip-
tional machinery such that the cloned ORFs are not
expressed, thus avoiding problems from lethality due to
troublesome gene products. Third, there are several
expression and epitope-tagging vector options for the sub-
sequent study of proteins encoded by the cloned ORFs,
allowing a variety of approaches to studying their func-
tions. The high efficiency also lends itself to high through-
put approaches that are suitable for automation.
A total of 2071 unique primer pairs were successfully
designed for the 2189 annotated ORFs of the FA1090
genome [13] and 61 ORFs of the GGI [14,15]. These prim-
ers were gene specific, and their termini contain sequences
for recombination cloning into the entry vector,
pDONR221 (Invitrogen). All primers were designed such
that the final recombination product yielded the native
start codon at the 5' end of the gene, including the 206 of
the 229 predicted ORFs with alternative (non-ATG) start
codons. Since nearly half of the genes of this group (110/
229) are annotated (that is encode putative proteins with
significant similarity to proteins of known function), it is
very possible that they are functional genes in the gono-
coccus and were thus included in the clone set design.
Whether or not they encode functional proteins will ulti-
mately depend on the results of future expression and
mutation studies. The 23 ORFs of this subset not included
were less than 400 bp in length and considered too small
for the Gateway® system (see below). For the 149 ORFs
encoding predicted proteins with an amino-terminal sig-
nal sequence (as identified by PSORT [16] and SignalP
[17]), sequences encoding the signal sequence were
removed and an ATG start codon placed at the 5' end ofPage 2 of 11
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problems of expression of hydrophobic signal sequences
and to facilitate future expression and targeting studies for
such recombinant proteins.
The primer design strategy was iterative, starting with an
annealing temperature range of 62°–72°C and primer
length set to 18 nt. All ORFs were included in the first iter-
ation, and those ORFs for which a primer pair was not
selected were subjected to subsequent iterations. In each
subsequent iteration the primer length parameter was
increased by one, up to a maximum primer length of 34
nt. Primers larger than this were not designed in part due
to cost and convenience of oligo synthesis in our 96-well
format. Next, the annealing temperature range was
expanded 5°C in both the positive and negative directions
and each primer size from 18 to 34 nt was tried again. No
further iterations were attempted after the annealing tem-
perature range exceeded 47°–87°C. Failing to meet either
of these criteria resulted in a primer pair not being
designed for the ORF. There were a total of 177 ORFs for
which no primers were designed (see Additional file 2),
174 from FA1090 and 3 from the GGI. Most of these ORFs
(165/177 = 93%) were less than 500 bp in length, and
were not included since the Gateway® system is reportedly
less efficient for cloning fragments of this small size.
To each of the gene specific primer sequences for the 5'
ends of the ORFs was added a 21 nt sequence including a
consensus ribosome binding site (Shine-Dalgarno
sequence). To each of the gene specific primer sequences
for the 3' ends of the ORFs was added 20 nt corresponding
to the 3' end of the attB2 site necessary for recombination
into pDONR221. These were the primary PCR primers,
the sequences of which are available on request. A single
pair of primers was then designed for a secondary ampli-
fication to generate gene specific products containing the
attB sites for the recombinatory cloning step. The 5' sec-
ondary primer contained the 24 nt attB1 tail and the 21 nt
sequence (Shine-Dalgarno) common to all of the primary
5' primer sequences. The 3' secondary primer contained
the remaining 10 nt of the attB2 site and the 20 nt attB2
sequence common to all of the primary 3' primer
sequences. The attB sequences were as recommended in
the Gateway® manual.
PCR amplification of ORFs
The first round of PCR, using gene specific primers,
included a total of 2071 different primer pairs. Plates 1
and 2 were organized as pilot reactions and contained
primers designed to amplify products ranging from 143
bp to 3485 bp in length. Genomic DNA from N. gonor-
rhoeae strain FA1090 was used as a template for the reac-
tions. Agarose gel analysis of the amplicons showed that
173 of the 192 reactions yielded a product of the expected
size, an efficiency of 90%. Plates 3–21 were then arranged
with increasing size of expected product, with plate 3 con-
taining the smallest products and plate 21 the largest. Sev-
eral primer pairs (from plates 1 and 2) were included in
plates 3–21 as internal controls. Plate 22 was an addi-
tional control plate, with one half of the plate (rows A-D)
duplicated on the other half (rows E-H). Plate 23 corre-
sponded to the genes of the GGI present in strain MS11
[14,15], and MS11 genomic DNA was used as the tem-
plate for this plate of reactions. 5 µl of each reaction from
the first round of PCR of each plate were run on agarose
gels and scored for production of a product and whether
it was of the expected size. The results showed 89% of the
reactions to produce a product of the correct size.
Following the primary amplification with gene specific
primers, all products (in the original 96-well format) were
diluted 1:100 and an aliquot subjected to a secondary
amplification using a pair of primers corresponding to the
sequences common to all of the amplicons, and including
additional sequences to generate a complete attB site for
the cloning reaction. Aliquots of the secondary amplifica-
tion were then used directly in the recombination reaction
to generate entry clones.
Construction of the library
Secondary amplicons were inserted into pDONR221 by in
vitro recombination between the attB sites introduced at
the ends of the amplicons and the attP sequences of the
vector, maintaining the 96-well format arrangement.
Cloning reactions were then transformed into E. coli strain
DH5α and a portion of the transformation mix plated on
LB plates containing kanamycin. Individual transform-
ants were screened by PCR to determine the presence of
and size of the insert. For the first round of screening, four
independent transformants from each reaction were
screened, maintaining the original 96-well format. A
product of 350 bp was observed if no insert was present, a
positive clone was identified as having a product 350 bp
larger than the size of the corresponding primary PCR
product.
For the initial set of 2147 transformation reactions, clones
corresponding to 1165 genes were identified in the first
four transformants screened, an efficiency of 54%. This
efficiency varied greatly with the predicted size of insert,
the smallest inserts (plate 3) were 83% positive in the first
four screened and the next largest inserts (plate 20) had
17% positive in the first four screened. Plate 21, which
had the largest inserts, only yielded 3 transformants as
positive after several rounds of screening. Additional
transformants for those clones not identified in the first
round of screening were individually cultured, screened
by PCR, and positive clones frozen down as they werePage 3 of 11
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clones.
Following the initial rounds of screening, a list of missing
clones was generated and the amplification and cloning
steps repeated, optimizing several parameters and analyz-
ing on an individual basis. This approach yielded an addi-
tional 283 clones, for a total of 1802 which were
subsequently sequenced. Arrangement of the clones in
plates for the master set and for sequencing was on an "as
identified" basis, such that they are not arranged as in the
original 96-well format. Each of the 21 plates contain via-
ble clones in up to 95 of the 96 available positions, with
position H12 (and additional wells on some plates) left
empty for controls, providing a unique identity for several
of the plates.
Sequence verification of the clones
Transformants identified as having an insert of the pre-
dicted size were grown in 96-well plates and DNA isolated
for sequence analysis. DNA isolation and sequencing was
done by at the Human Genome Sequencing Center at Bay-
lor College of Medicine (HGSC) using the same set of
primers used to screen transformants for insert size.
Sequence reads were posted onto an HGSC website and
subsequently downloaded by FTP. DNA reads were proc-
essed initially using the STADEN DNA analysis software
package [18]. Binary files were converted into .exp files
using PREGAP4 to generate text files for each individual
sequence read, with sequence quality cutoffs. These data
are provided in Additional File 1 (AF1 exp sequence
files.zip), and a description of the labelling scheme for the
files is in the Methods section.
The data were next analyzed by BLAST [19] against the N.
gonorrhoeae genome sequence database [13]. Clones
expected to contain inserts from the GGI, not present in
FA1090, were analyzed by BLAST 2 [20] using sequence of
the individual GGI ORFs ([15], GenBank accession
number AY803022). BLAST results were then manually
tabulated in a file containing the expected gene for each
archived clone. Of the 1802 sequenced clones, 58 were
expected to be duplicates, leaving 1744 unique clones
expected in the clone set. 1550 of the sequences were read-
able and corresponded to a predicted ORF from N. gonor-
rhoeae, 1399 of them unique, corresponding to 151
duplicates. Some duplicates were expected, and the
remainder likely due to cross contamination from neigh-
boring wells. Of those sequence validated, 55 were not in
positions predicted. Most of these were due to human
error, such as obvious well transpositions and numbering
transpositions. 26 of these, however, had inserts in a back-
wards orientation and were incomplete. These clones will
not be usable in subsequent recombination reactions
using the Gateway® system. Together, these data indicate
that at present we have a collection of 1672 individual
clones from N. gonorrhoeae, 48 of which are from the GGI,
and 83% of which have been sequence validated. A list of
genes in the clone set with sequencing result information
can be found in Additional File 2 (AF2 NG clone set seq
status.xls).
Overexpression of randomly chosen ORFs
In order to examine the flexibility of using the clone set to
construct various derivatives for which the Gateway® sys-
tem was designed, three randomly selected pDONR221
derivatives were used to create inducible glutathione-S-
transferase (GST) fusions. Plasmids containing ORFs
NG1490 (aspS, encodes aspartyl-tRNA synthetase),
NG1561 (xthA, encodes exodeoxyribonuclease III), and
NG1641 (pivNG, encodes a pilin gene inverting homolog,
PivNG) are predicted to encode native proteins of 9.6,
29.0, and 36.2 kdal respectively. Plasmid DNA of
pDONR221 derivatives containing these three genes were
recombined with the destination vector pDEST15, an N-
terminal GST fusion vector. The resulting recombinants
were then transformed into E. coli BL21-AI for expression
analysis. SDS-PAGE analysis of the proteins after a 2 hr
induction with 0.2% L-arabinose is shown in Figure 1.
The results show high levels of induction for each of the
fusion proteins, with the sizes as predicted (GST adds 29
kdal).
SDS-PAGE analysis of NG ORF-GST fusionsFigure 1
SDS-PAGE analysis of NG ORF-GST fusions. Equivalent 
amounts of total protein was boiled in sample buffer and 
electrophoresed on 10% polyacrylamide gels. Gels were 
stained with Coomassie Blue. Lane 1: MW markers; lane 2: 
NG1490(AspS)-GST, uninduced; lane 3: NG1490 induced 
(38.6 kdal); lane 4: NG1561(XthA)-GST uninduced; lane 5: 
NG1561 induced (58.0 kdal); lane 6: NG1641(PivNG)-GST 
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Since a very small portion of the secondary amplicons
were used for the cloning reactions (5 µl of a 50 µl reac-
tion), the remaining products were used to produce a set
of DNA arrays for gene expression analysis. Gel electro-
phoresis (data not shown) indicated that the efficiency
after the secondary amplification was 81%, representing
1681 ORFs of a total of 2071. To generate a more com-
plete DNA array, a second set of primers (360) were
designed to amplify internal portions of those ORFs not
visible following the secondary PCR. Primers to amplify
sequences of two small RNAs were also designed:
NG0892.1, ffs, encodes the 4.5S RNA component of the
gonococcal signal recognition particle [21]; and
NG0880.1, tmRNA, encodes an RNA that tags abnormal
proteins in the cell arising from stalled ribosomes and tar-
gets them for proteolysis [22]. Gel analysis of the ampli-
cons produced from the internal PCR primers showed 294
of the 362 to produce products of the expected size, for an
efficiency of 82%. Together, the cloning amplicons
(1681) and internal ORF and RNA amplicons (294) rep-
resent a minimum of 1975 ORFs of the N. gonorrhoeae
genome. This is a minimal estimate since all products
(regardles of gel result) were to be spotted, and some
products might be present, but at amounts too low to be
visualized. DNA samples were processed and spotted onto
glass slides as described in Methods. As a first test, the
arrays were hybridized with a Cy3-labelled random non-
amer oligonucleotide (Qiagen). A scan of the slide at 532
nm showed spots at the appropriate positions where DNA
had been spotted, and blank spots at the buffer control
spots. The next test was to hybridize the arrays with
labelled genomic DNA. Total DNA from N. gonorrhoeae
strain MS11 was digested with RsaI and labelled by
including Cy3-dCTP in a random-primed Klenow DNA
polymerase reaction (Roche Applied Science, Indianapo-
lis, IN). DNA arrays were hybridized and then scanned at
532 nm. Valid hybridization signals (at least one standard
deviation above background) were detected for 98% of
the spots expected to contain DNA, with those of the
MS11-specific island comparable in intensity to those of
FA1090 amplified DNA. Overall, the results showed valid
signals for 2035 individual genes, with several in dupli-
cate. The fact that this number is higher than expected
based on agarose gel analysis of the amplicons before
spotting (see above) indicates that some of the reactions
produced a product, but at amounts too low to be visual-
ized by ethidium bromide (EtBr) staining. Thus, these
arrays represent 90% (2035/2250) of the predicted ORFs
of N. gonorrhoeae (including 58 ORFs of the GGI; [14,15])
and 98% of those for which primers were designed.
Discussion
Despite the advent of antibiotics in the 1940's, disease
due to infection with N. gonorrhoeae remains a major
health problem worldwide. The reasons for this are multi-
fold. First, resistance to antibiotics by N. gonorrhoeae con-
tinues to rise [1,3,4]. In addition, treatment with high lev-
els of broad spectrum antibiotics (which is frequently
done since patients often do not return for follow up treat-
ment) kills many bacteria of the (often beneficial) normal
flora as well as the disease-causing microbe. Second, there
is an incredibly high frequency of asymptomatic gonococ-
cal infection, occurring in 5–10% of infected men and up
to 50% of infected women. This represents a major reser-
voir for transmission of the infection. Furthermore, undi-
agnosed and untreated gonococcal salpingitis can lead to
fallopian tube blockage. Partial blockage can result in
ectopic pregnancy, which can be life threatening, and
complete blockage of the fallopian tubes often leads to
infertility. Third, development of a vaccine to protect
against gonorrhea has been seriously hampered by the
observation that gonococcal infection does not elicit pro-
tective immunity [5]. Patients can be reinfected following
treatment, and can even be infected by multiple strains at
a given time. Thus, alternative treatments and preventa-
tive strategies for gonococcal infection are sorely needed.
As a first step in the identification of such alternative treat-
ments and preventatives, it will be necessary to more thor-
oughly understand the biology of the gonococcus and the
molecular mechanisms involved in its interactions with
the host environment. Much of the studies to date have
focussed primarily on identifying the molecules on the
surface of the bacterium that directly interact with the
host, and the toxic moieties involved in damage to host
cells. Many of the molecules identified are outer mem-
brane (OM) components [23-27], and iron utilization
proteins (reviewed in [28]). A few are secreted [29], or
shed in blebs [30-32]. There has also been significant
work in the identification of eukaryotic host cell receptors
for gonococcal surface proteins (reviewed in [10]).
Interactions between gonococci and epithelial cells are
beginning to be unraveled. Chen and Clark showed that
contact with Hec-1-B human endocervical epithelial cells
increases gonococcal infectiveness and that the process
involves, in part, de novo protein synthesis by the bacte-
rium [33]. The gonococcal type IV pilus (Tfp) and Opa
proteins promote attachment, invasion and trans-epithe-
lial trafficking. The mechanisms underlying Tfp- and Opa-
mediated virulence are not yet understood, but these sur-
face structures modulate a series of events in the infected
epithelial cell, among them Ca2+ fluxes [34,35], cortical
rearrangements [36], and receptor phosphorylation [37-
39]. Tfp retraction enhances the activation of stress-
responsive kinases and the transcription of cytoprotective
genes in the infected cell [40], and triggers the infected cell
to produce a molecule that alters bacterial motility behav-
ior [41]. Finally, binding of gonococci to primary urethralPage 5 of 11
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other observations indicate that gonococcal infection
requires the active participation of both the bacterium
and the host cell.
The recent completion of the annotated genome sequence
of N. gonorrhoeae [13,43], coupled with the development
of high throughput methods for the analysis of gene
expression and function, provide an opportunity to signif-
icantly advance the study of gonococcal biology and
pathogenesis. Like many sequenced genomes, nearly half
(44%) of the genes of the annotated gonococcal genome
encode hypothetical proteins of unknown function. Fur-
thermore, many of the annotations are based on homolo-
gies at the nucleotide and/or amino acid level, and the
actual function of the gonococcal proteins have not been
demonstrated. In order to realize the full potential of
information gleaned from the genome sequence of this
(and any) organism, it will be necessary to assign func-
tions to all of the genes of the genome. The newly emerg-
ing fields of functional genomics and proteomics offer
much promise towards achieving the goal of eventual
assignment of functions for each and every gene in a given
organism.
In this work, we describe the initial phases of the construc-
tion of an expression-capable clone set representing the
annotated ORFs of the gonococcal genome using a recom-
bination-based cloning system. The advantages of the sys-
tem used for this set are numerous. 1) The original
sequences in the clone set contain only the ORFs, not the
gene expression sequences, thus avoiding the issue of
expression-related lethality of the recombinants. 2) The
clones can be transferred to a number of expression sys-
tems (prokaryotic and eukaryotic), allowing the regula-
tion of genes for overproduction of proteins, or the
production of proteins out of the context of the particular
environments so as to study their functions. 3) The clones
can also be transferred to vectors that result in epitope
fusions, such as hexa-histidine, GST, green fluorescent
protein (GFP), Lumio™, etc., to the proteins of interest.
Protein fusions are useful in localizing proteins (within
the bacterium or infected cell), in determining protein-
interacting partners, in allowing smaller step purification
protocols for structural and activity studies, and for anti-
body production. This ability has been demonstrated by
constructing IPTG-inducible GST-fusions from three ran-
dom clones from this set (Fig. 1). 4) The clone set is also
catalogued in such a way that individual clones of interest
are easily identified and recovered from the clone bank
(see Additional file 2). 5) Entry clones can also be used to
create knockouts by in vitro transposition [44,45] or shut-
tle mutagenesis [46] followed by transformation into nat-
urally competent gonococci [47]. This system is also
ammenable to automation, thus increasing the potential
output and consistency in the data obtained.
The N. gonorrhoeae clone set thus far includes 1672 of the
2250 predicted ORFs of the genome [13], of which 83%
are sequence-validated. Included in this set are 48 of the
61 ORFs of the MS11 GGI [14,15]. While this clone set is
not yet complete, we believe these initial efforts have
resulted in generating a valuable resource for the Neisseria
research community. It is hoped that others in the com-
munity will share compatible reagents and add to the
clone set, making it more comprehensive over time.
Coupled to the clone set construction, a PCR-amplicon
based DNA microarray was generated. DNA microarrays
are a powerful tool that allow one to measure relative
transcript levels for essentially each gene of the genome
simultaneously. These DNA arrays represent 2035 ORFs
of the N. gonorrhoeae genome: 1977 from strain FA1090
[48] and 58 from the MS11 GGI [14], comprising 90% of
the genes of the genome. Preliminary studies show that
these arrays are suitable for examining global gene expres-
sion in N. gonorrhoeae.
Many bacterial pathogens are known to respond to
changes in their physical environment, often integrating
responses to several environmental signals via complex
regulatory networks to control expression of a variety of
genes [49-53]. The examples of regulatory systems charac-
terized in gonococci are few, with the best characterized
being the response to iron availability [54,55] and antimi-
crobial compounds [56,57]. The advent of microarray
technologies has opened avenues of research on global
gene expression in both prokaryotes and eukaryotes, pro-
viding opportunities for studying a variety of organisms,
including such genetically intractable microbes as
Trepanema pallidum [58] and Chlamydia trachomatis [59].
Thus, the use of DNA arrays will allow us to more fully
explore the response of N. gonorrhoeae to environmental
signals at the gene expression level. Since genes are typi-
cally only transcribed when the gene product function is
required, expression profiles and cluster analyses will
allow us to begin to determine the functions of unknown
genes in the genome. Thus far, use of these DNA arrays has
led to the identification of a regulator involved in the
modulation of gonococcal gene expression upon adher-
ence to epithelial cells in [45].
In summary, the tools described in this work represent a
resource which will facilitate experiments to dissect the
molecular mechanisms of gonococcal pathogenesis on a
global scale. Combining these tools with the gonococcal
infection models (tissue culture [60], organ culture [61-
63], and the mouse model [64]), will allow us to make sig-
nificant advances in the study of this important pathogen,Page 6 of 11
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therapeutics with which to treat and prevent gonococcal
disease.
Methods
Gene predictions and initial sequence preparation
All ORF IDs for strain FA1090 reference records can be
found at the STDGEN Neisseria gonorrhoeae annotated
genome sequence database [13]. All gene sequences were
prepared to include the natural start and stop codons.
NG0540 and NG0634 have internal stop codons in the
sequence database, and nothing was done to correct for
this. Sequences of the ORFs of the MS11 GGI [15] have
been deposited in the GenBank database with the acces-
sion number AY803022.
Signal peptide identification
In order to determine whether the ORFs contained signal
sequences, the programs PSORT [16] and SignalP [17]
were employed. If both programs predicted a cleavable
signal peptide for a given ORF sequence, that constituted
"high support". The result of the signal peptide analyses
showed 149 sequences with high support for a signal pep-
tide. For those gene nucleotide sequences with a high sup-
port signal peptide, the nucleotide sequence representing
the signal peptide was removed prior to cloning primer
design. When both programs predicted different cleavage
sites, the cleavage site that represented the shorter signal
peptide was chosen. The rationale for this choice was that
it would be better to include a bit of the signal peptide in
the PCR product than to exclude a bit of the mature pro-
tein in the PCR product.
Primer design
In the first cycle, the forward and reverse primers were
fixed at the same length. This was due to the ease at which
Primer3 [65] could be used. The input file was all gene
sequences for which no signal peptide sequence was
detected (see above). For the second cycle, the prim.aux
file was manually inspected. This file contained informa-
tion about successful primer picks where only a left or
right primer could be picked. The strategy was to combine
primers of different length. The potential for primer-
dimer formation using this strategy was also assessed.
N.g. ORF cloning
Primers for each of the genes were purchased from Illu-
mina, Inc (San Diego, CA) and were designed to add
sequences corresponding to part of the attB site necessary
for recombination into the Gateway® entry vector,
pDONR221 (Invitrogen). Primary amplification was
done using genomic DNA at a concentration of ~10 ng/
reaction and gene specific primers at 2.5 µM. Reaction mix
contained dNTPs, reaction buffer, MgCl2 and Taq
polymerase as recommended by the manufacturer
(Roche). Reactions conditions for primary PCR were as
follows: denaturation at 94°C for 10 min; 10 cycles of
94°C 30 sec, 50°C 1 min, 74°C 1–5 min (depending on
length of predicted product); 20 cycles of 94°C 30 sec,
55°C 1 min, 74°C 1–5 min (depending on length of pre-
dicted product); and a final extension at 74°C for 10 min.
Following the primary amplification with the primer set,
products were diluted 1:100 and 1 µl used as template for
a secondary amplification using a pair of primers corre-
sponding to the partial attB site common to all of the
amplicons, and including additional sequences to gener-
ate a complete attB site for the cloning reaction. Reactions
conditions for secondary PCR were as follows: denatura-
tion at 94°C for 1 min; 5 cycles of 94°C 15 sec, 45°C 30
sec, 68°C 2 min; 15 cycles of 94°C 15 sec, 55°C 30 sec,
68°C 2 min. 5 µl of the 50 µl PCR was removed and used
for cloning, and the remainder used for agarose gel analy-
sis and printing of DNA arrays (N.g.array version 1.0, see
below). Cloning reactions were performed according to
the manufacturer's instructions (Invitrogen), transformed
into E. coli strain DH5α, and transformants selected for
kanamycin resistance. Individual transformants were
picked in to wells of 96-well plates containing 100 µl L
broth containing kanamycin (50 mg/l) and the same
toothpick then used to place a small amount of bacteria
directly into another plate containing a PCR cocktail. PCR
was done using the M13 universal primers, which flank
the att sites of the entry vector, pDONR221. A product of
350 bp was observed if no insert was present, providing an
internal control for the PCR reactions. Individual clones
were identified, stocked in duplicate, and grown for DNA
isolation for sequencing.
Sequencing
Sequencing runs from each end of the insert of each of the
clones was determined to verify the ORF inserted. Com-
plete sequence verification, (ie. both strands completely
across the insert) was not done as it was determined to be
impractical. DNA sequencing reactions were performed at
the Baylor College of Medicine HGSC. Additional File 1 is
a zipped file containing each of the sequence reads as .exp
files generated using PREGAP4, and can be opened and
read using word processing software. The file is separated
into folders labelled SeqPlate #, which refers to sequenc-
ing plate number (1–21), and corresponds to the SP# des-
ignation in the list of clones in Additional File 2. SP18
sequencing reactions were done twice (SeqPlate 18-1, Seq-
Plate 18-2) as a sequencing reaction control, and the reac-
tions of SP5 were analyzed three times (SeqPlate 5-1,
SeqPlate 5-2, SeqPlate 5-3) as controls. SP20 does not
exist, SP22 was not sent for sequencing, and the quality of
SP17 sequence was too poor to be readable. The naming
of the individual read files is as follows: BGACA(project
code) # (1, 2, or 3 = reaction) D or F (primer D = forward,
F = reverse) # (box, not same as SP) # (01–96; well, 1 = A1,Page 7 of 11
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BGACA3D1701A (found in SeqPlate 1 file) corresponds
to SP1 well A1 sequenced with the forward primer (5' end
of ORF), result from the third reaction and the first gel.
Gene expression analysis
pDONR221 derivatives chosen from the clone set were
recombined with the destination vector, pDEST15 (Invit-
rogen), an N-terminal GST fusion vector. Plasmid DNA
from the pDONR221 derivatives was isolated and incu-
bated with pDEST15 in a LR recombination reaction per-
formed according to the manufacturer's instructions. The
recombination mixes were transformed into E. coli DH5α
and transformants were selected on LB plates containing
50 mg/l Carbenicillin (Cb50). To test the possibility of
false positive clones, the overexpression clones were
tested for growth on chloramphenicol (20 mg/l), on
which expression recombinants should not grow since the
chloramphenicol resistance gene of pDEST15 is replaced
by the insert. The resulting plasmids were purified and
transformed into E. coli BL21-AI (Invitrogen) which
expresses T7 RNA polymerase from the araBAD promotor,
and transformants were selected on LB Cb50 plates. BL21-
AI strains containing the pDEST15 derivatives were grown
overnight and used to inoculate fresh LB medium con-
taining Cb50 to an OD600 of 0.05. Expression of the GST-
fusion proteins in E. coli BL21-AI was induced at an OD600
of 0.5 by addition of L-arabinose to a final concentration
of 0.2%. Aliquots were removed after 2 hr and total pro-
teins electropheresed on 10% polyacrylamide SDS gels
[66].
DNA microarray construction
PCR amplicons remaining from the cloning reactions
(described above) were concentrated and then spotted in
duplicate onto TeleChem SuperAmine glass slides (Tel-
eChem International, Inc., Sunnyvale, CA) using a Gen-
eMachines Omnigrid 100 (GeneMachines, Inc., San
Carlos, CA) with 16 TeleChem Chipmaker 3 pins at the
Genome Technology Support Facility (GTSF) at Michigan
State University. Preparation of probes and hybridization
conditions were as described [45]. Hybridized microarray
slides were scanned using a GenePix 4000B scanner (Axon
Instruments, Union City, CA) and images were processed
and analyzed using GenePix version 4.1 software.
Availability of clone set
The master library was used to generate a limited set of
stock plates, which are stored at various locations as refer-
ence stocks. An additional set is stored at Michigan State
University and is regarded as the working copy, which is
the sole source of material for distribution. Interested par-
ties should contact Cindy Arvidson (corresponding
author) to arrange for a copy of the clone set. The clones
will only be available as an intact set, individual clones or
groups of clones are not available.
Availability of microarrays
DNA arrays will be generated by re-amplification of the
amplicons used for the recombination-cloning reactions
using primers recognizing the common sequences at the
ends of the amplicons at the MSU GTSF. Interested parties
should contact Cindy Arvidson (corresponding author) to
request slides, which will be produced upon request.
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